Nasdaq:US$13.30 (+0.08) | HKEX:HK$20.50 (-0.70) | AIM:£2.12 (-0.07)
Search Result
Previous Article   |   Next Article
Announcements & Press Releases, Oncology / Immunology | 22 Nov 2007

Chi-Med Plans to Initiate Global Phase IIb Trials of its Lead Anti-Inflammatory Drug Candidate, HMPL-004, in Ulcerative Colitis Patients

1 items
a071122